iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sees Strong Trading Volume – Here’s What Happened

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) shares saw unusually-strong trading volume on Monday . Approximately 732,323 shares were traded during trading, an increase of 686% from the previous session’s volume of 93,159 shares.The stock last traded at $88.29 and had previously closed at $88.00.

iShares U.S. Pharmaceuticals ETF Trading Up 0.9%

The company has a market capitalization of $973.40 million, a price-to-earnings ratio of 17.75 and a beta of 0.49. The firm has a 50-day moving average price of $87.31 and a 200-day moving average price of $85.05.

Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF

Large investors have recently modified their holdings of the stock. Mather Group LLC. bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth $38,000. EFG International AG bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 4th quarter worth $38,000. Assetmark Inc. boosted its stake in shares of iShares U.S. Pharmaceuticals ETF by 203.9% during the 4th quarter. Assetmark Inc. now owns 465 shares of the company’s stock worth $39,000 after acquiring an additional 312 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its stake in shares of iShares U.S. Pharmaceuticals ETF by 35.0% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock worth $39,000 after acquiring an additional 120 shares in the last quarter. Finally, Blueline Advisors LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 4th quarter worth $41,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.